最新医学　別冊　新しい診断と治療のABC19　骨髄異形成症候群　血液2

出版社： 最新医学社
発行日： 2004-02-25
分野： 臨床医学：一般  >  雑誌
雑誌名：
特集： 骨髄異形成症候群　血液2
電子書籍版： 2004-02-25
書籍・雑誌
≪全国送料無料でお届け≫
品切れ

5,500 円(税込)

電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

4,400 円(税込)

購入する

目次

  • 最新医学　別冊　新しい診断と治療のABC19　骨髄異形成症候群　血液2

    ―目次―

    第１章　骨髄異形成症候群の概念・定義
    概念・定義・分類 　
    疫学 　
    治療誘発性MDS 　
    小児MDS 　

    第２章　骨髄異形成症候群の病理・病態生理
    血球のクローン性 　
    遺伝子異常 　
    染色体とテロメア 　
    アポトーシス　
    サイトカインと骨髄基質　
    免疫異常 　

    第３章　骨髄異形成症候群の診断
    血球異形成の診断 　
    検査所見からみたMDSの診断 　
    骨髄細胞密度の評価　
    診断基準　
    鑑別診断　

    第４章　骨髄異形成症候群の管理・治療
    MDS診療における感染症の管理・治療　
    QOLを重視した補助療法　
    治療薬剤：1　免疫抑制療法 　
    治療薬剤：2　MDSのサイトカイン療法　
    治療薬剤:3　MDS特にRAに対する在来薬物療法 　
    抗アポトーシス療法 　
    化学療法:1　標準的化学療法 近畿大学 金丸昭久
    化学療法:2　低用量化学療法 　
    分化誘導療法　
    幹細胞移植療法 　
    経過・予後　
    医療経済 　

    第５章　骨髄異形成症候群のガイドライン
    骨髄異形成症候群のガイドライン作りに向けて 　

    座談会　骨髄異形成症候群の診断・治療における最近の話題

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

第1章 骨髄異形成症候群の概念・定義

P.14 掲載の参考文献
1) 吉田弥太郎:骨髄異形成症候群の臨床, 第2版. 新興医学出版, 東京, 2000.
 
2) Yoshida Y:Hypothesis. Apoptosis may be the mechanism responsible for the premature intramedullary cell death in the myelodys-plastic syndrome. Luekemia 7:144-146, 1993.
 
3) Bowen DT:Genetic predisposition to myelodysplastic syndromes. Luek Res 27(Suppl 1):S8, 2003.
 
4) 吉田弥太郎:骨髄異形成症候群研究の100年. 日内会誌 91:141-145, 2002.
 
5) Bennett J M, et al:Proposal and classfication of the myelodysplastic syndromes. Br J Haematol 51:189-199, 1982.
 
6) Vardiman J W, et al:The World Health Organization(WHO) classification of the myeloid neoplasms. Blood 100:2292-2232, 2002.
PubMed
7) Bennett J M:World Health Organization classification of the acute leukemias and myelodysplastic syndrome. Int J Hematol 72:131-133, 2000.
PubMed
P.21 掲載の参考文献
1) Bennett J M, et al:Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51(2):189-199, 1982.
PubMed
2) Fernandez-Ferrero S, et al:Dyshaemopoietic bone marrow features in healthy subjects are related to age. Leuk Res 25(2):187-189, 2001.
PubMed
3) Cartwright R A:Incidence and epidemiology of the myelodysplastic syndromes. In:The Myelodysplastic Syndromes(Mufti G J, Galton DAG), p23-31. Churchill Livingstone, Edinburgh, Scotland, 1992.
 
4) Cartwright R A, et al:The descriptive epidemiology of leukaemia and related conditions in parts of the United Kingdom 1984-1993, p9-100. Leukaemia Research Fund, London, 1997.
 
5) Williamson P J, et al:Establishing the incidence of myelodysplastic syndrome. Br J Haematol 87(4):743-745, 1994
PubMed
6) Aul C, et al:Age-related incidence and other epidemiological aspects of myelodysplastic syndromes. Br J Haematol 82(2):358-367, 1992.
PubMed
7) Radlund A, et al:Incidence of myelodysplastic syndromes in a Swedish population. Eur J Haematol 54(3):153-156, 1995.
 
8) Maynadie M, et al:Epidemiological characteristics of myelodysplastic syndrome in a well defined French population. Br J Cancer 74(2):288-290, 1996.
 
9) Bauduer F, et al:Epidemiology of myelodysplastic syndromes in a French general hospital of the Basque country. Leuk Res 22(3):205-208, 1998.
 
10) Reizenstein P, et al:Increasing Prevalence of the myelodysplastic syndrome. An international Delphi study. Anticancer Res 11(3):1069-1070, 1991.
PubMed
11) Aul C, et al:Increasing incidence of myelodysplastic syndromes:real or fictitious? Leuk Res 22(1):93-100, 1998.
PubMed
12) Shimizu H, et al:Prevalence of the myelodysplastic syndromes in Japan. Int J Hematol 61(1):17-22, 1995. Bennett J M, personal communication.
 
14) Luna-Fineman, S, et al:Myelodysplastic and myeloproliferative disorders of childhood:a study of 167 patients. Blood 93(2):459-466, 1999.
PubMed
15) Tuzuner N, et al:Hypocellular myelodysplastic syndromes(MDS):new proposals. Br J Haematol 91(3):612-617, 1995.
PubMed
16) Steensma D P, et al:Myelodysplasia with fibrosis:adistinct entity? Leuk Res 25(10):829-838, 2001.
 
17) Stetler-Stevenson M, et al:Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome. Blood 98(4):979-987, 2001.
PubMed
18) Miyazato A, et al:Identification of myelodys-plastic syndrome-specific genes by DNA micro array analysis with purified hematopoietic stem cell fraction. Blood 98(2):422-427, 2001.
 
19) Aul C, et al:Epidemiological features of myelodysplastic syndromes:results from regional cancer surveys and hospital-based statistics. Int J Hematol 73(4):405-410, 2001.
PubMed
20) Hamblin T J:Epidemiology of the myelodys-plastic syndromes. In:The Myelodysplastic Syndromes:Pathobiology and Clinical Management(Bennett J M), p15-27. Marcel Dekker, New York, 2002.
 
P.30 掲載の参考文献
1) Darrington D L, et al:Incidence and charac-terization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies. J Clin Oncol 12(12):2535-2542, 1994.
 
2) 谷脇雅史, 他:白血病の分子発症機序(染色体と癌遺伝子). 日内会誌 92(6):942-949, 2003.
 
3) Pui C H, et al:Secondary acute myeloid leukemia in children treated for acute lymphoid leukemia. N Engl J Med 321(3):136-142, 1989.
PubMed
4) Pedersen-Bjergaard J, et al:High risk of therapy-related leukemia after BEAM chemotherapy and autologous stem cell transplantation for previously treated lymphomas is mainly related to primary chemotherapy and not to the BEAM-transplantation procedure. Leukemia 11(10):1654-1660, 1997.
PubMed
5) Wang P, et al:dic(5;17):a recurring abnormality in malignant myeloid disorders associated with mutations of TP53. Genes Chromosomes Cancer 20(3):282-291, 1997.
PubMed
6) Horiike S, et al:Configuration of the TP53 gene as an independent prognostic Parameter of myelodysplastic syndrome. Leuk Lymphoma 44(6):915-922, 2003.
PubMed
7) Cimino G, et al:Infant acute leukemias show the same biased distribution of ALL1 gene breaks as topoisomerase II related secondary acute leukemias. Cancer Res 57(14):2879-2883, 1997.
PubMed
8) Arai Y, et al:The inv(11)(p15q22) chromosome translocation of de novo and therapy-related myeloid malignancies results in fusion of the nucleoporin gene, NUP98, with the putative RNA helicase gene, DDX10 Blood 89(11):3936-3944, 1997.
PubMed
9) Gu BW, et al:Major form of NUP98/HOXC11 fusion in adult AML with t(11;12)(p15; q13) translocation exhibits aberrant trans-regulatory activity. Leukemia. Leukemia 17(9):1858-1864, 2003.
 
10) Krishnan A, et al:Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma:an assessment of risk factors. Blood 95(5):1588-1593, 2000.
PubMed
11) Lillington D M, et al:Detection of chromosome abnormalities pre-high-dose treatment in patients developing therapy-related myelodysplasia and secondary acute myel-ogenous leukemia after treatment for non-Hodgkin's lymphoma. JCO 19(9):2472-2481, 2001.
 
12) Wiemels J L, et al:A lack of a functional NAD(P) H:quinone oxidoreductase allele is selectively associated with pediatric leukemias that have MLL fusions. United Kingdom Childhood Cancer Study Investigators. Cancer Res 59(16):4095-4099, 1999.
 
13) Felix CA, et al:Association of CYP3A4 genotype with treatment-related leukemia. Proc Natl Acad Sci USA 95(22):13174-13181, 1998.
 
14) Sasai Y, et al:Genotype of glutathione S-transferase and other genetic configurations in myelodysplasia. Leuk Les 23(11):975-981, 1999.
 
15) 谷脇雅史, 他:白血病のFISH解析. 内科 92:450-453, 2003.
 
16) 上田龍三:二次白血病の病態と分子機序. 日内会誌 86:243-249, 1997.
 
17) 阿部達生:二次自血病. 癌と化療 26:1999-2008, 1999.
 
P.41 掲載の参考文献
1) MDS委員会:第1回MDS委員会活動報告. 日小血会誌 15:54-56, 2001.
 
2) Sasaki H, et al:Myelodysplastic syndrome in childhood:a retrospective study of 189 patients in Japan. Leukemia 15:1713-1720, 2001.
PubMed
3) Hasle H, et al:A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases. Leukemia 17:277-282, 2003.
 
4) Niemeyer C M, et al:Chronic myelomonocytic leukemia in childhood:a retrospective analysis of 110 cases. Blood 89:3534-3543, 1997.
PubMed
5) Wechsler J, et al:Acquired mutations in GATal in the megakaryoblastic leukemia of Down syndrome. Nat Genet 32:148-152, 2002.
 
6) Manabe A, et al:Third International Symposium on Myelodysplastic Syndromes in Childhood. Int J Hematol, 78:475-476, 2003.
PubMed
7) 谷ヶ崎博, 他:Fanconi貧血の新しい診断法の開発. Int J Hematol 73(Suppl 1):203, 2001.
 
8) Dale D C, et al:Mutations in the gene encoding neutrophil elastase in congenital and cyclic neutropenia Blood 96:2317-2322, 2000.
PubMed
9) Bader-Meunier B, et al:Refractory anaemia and mitochondrial cytopathy in childhood. Br J Haematol 87:381-385, 1994
PubMed
10) Janov A J, et al:Diamond-Blackfan anemia Natural history and sequelae of treatment. Medicine 75:77-87, 1996.
PubMed
11) Willig T N, et al:Mutations in ribosomal protein S19 gene and Diamond Blackfan anemia:wide variations in phenotypic expression. Blood 94:4294-4306, 1999.
PubMed
12) Bader-Meunier B, et al. Occurrence of myeloprohferative disorder in patients with Noonan syndrome. J Pediatr 130:885-889, 1997.
PubMed
13) Tartaglia M, et al:Somatic mutation in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat Genet 34:148-150, 2003,
PubMed
14) Niemeyer C, et al:Differentiating juvenile myelomonocytic leukemia form infectious disease. Blood 91:365-367, 1998[letter].
 
15) 長谷川大輔, 他:JMML.血液フロンティア 13:1227-1235, 2003.
 
16) MDS 委員会:小児骨髄異形成症候群(MDS)診断の手引き. 日小血会誌 13:381-393, 1999.
 
17) 在家裕司, 他:小児のRAEB-AML-M6症候群について. Int J Hematol総会号 195, 2003.
 
18) 大塚欣敏他:小児MDSにおけるAML型寛解導入療法の効果:小児 MDS治療研究会 MDS99. Int J Hematol 総会号 195, 2003.
 
19) Manabe A, et al:Allogeneic hematopoietic stem cell transplantation for 27 children with juvenile myelomonocytic leukemia diagnosed based on the criteria of the International JMML Working Group. Leukemia 16:645-649, 2002.
 
20) Manabe A, et al:Experience on MDS and JMML from Japan. Myelodysplastic and myeloproliferative disorders in children(Lopes LF, et al, eds), p317-324. Lemar Livraria Publishers, Sao Paulo, Brazil, 2003.
 

第2章 骨髄異形成症候群の病理・病態生理

P.50 掲載の参考文献
1) Heaney M L, et al:Myelodysplasia. N Engl J Med 340(21):1649-1660, 1999.
PubMed
2) Saitoh K, et al:Chromosomal target cell of Myelodysplastic syndrome with chromoso-mal abnormality of trisomy 8. Blood 92(8):2886-2892, 1998.
 
3) Takahashi N, et al:Lineage involvement of stem cells bearing the Philadelphia chromosome in chronic myeloid leukemia in the chronic phase as shown by a combination of fluorescence-activated cell sorting and fluorescence in situ hybridization. Blood 92(12):4758-4763, 1998,
 
4) Miura I, et al:Involvement of NK cells in patients with myelodysplastic syndrome carrying monosomy 7 revealed by the application of fluorescence in situ hybridization(FISH) to cells collected by means of fluorescence activated cell sorting(FACS). Br J Haematol 110(4):876-879, 2000.
 
5) Miura L et al:Molecular cytogenetics of stem cells:Target cells of chromosomal aberra tions as revealed by the aplication of fluorescence in situ hybridization to fluorescence-activated cell sorting. Int J Hematol 72(3):310-317, 2000.
 
6) Oosterveld M, et al:The presence of an HLA-identical sibling donor has no impact on outcome of patients with high-risk MDS or secondary AML(sAML) treated with intensive chemotherapy followed by transplantation:results of a prospective study of the EORTC, EBMT, SAKK and GIMEMA Leukemia Group (EORTC study 06921). Leukemia 17(7):859-868, 2003.
PubMed
7) Nilson L, et al:Isolation and characterization of Hematopoietic progenitor/stem cells in 5q-deleted myelodysplastic syndromes:evidence for involvement at the Hematopoietic stem cell level. Blood 96(6):2012-2021, 2000.
 
8) Nilson L, et al:Involvement and functional impairment of the CD34+ Cd38-Thy-1+ Hematopoietic stem cell pool in myelodys-plastic syndromes with trisomy 8. Blood 100(1):259-267, 2002.
 
9) Miura I, et al:Discordant results indicating monosomy 8 from FISH and trisomy 8 from chromosome analysis in a patient with chronic lymphocytic leukemia. Leuk Res 24(4):367-369, 2000.
 
P.57 掲載の参考文献
1) Yokota S, et al:Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines. Leukemia 11:1605-1609, 1997.
 
2) Golub T R, et al:Fusion of PDGF receptor βto a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5:12) chromosomal translocation. Cell 77:307-316, 1994.
 
3) Bos J L:Ras oncogenes in human cancer. Cancer Res 49:4682-4689, 1989.
PubMed
4) Hirai H, et al:Apoint mutation at codon 13 0f the N-ras oncogene in myelodysplastic syndrome. Nature 327:430-432, 1987.
 
5) Morishita K, et al:Retroviral activation of a novel gene encoding a zinc finger protein in IL-3-dependent myeloid leukemia cell lines. Cell 54:831-840, 1988.
PubMed
6) Morishita K, et al:Expression of the Evi-1 zinc finger gene in 32Dc13 myeloid cells blocks granulocytic differentiation in response to granulocyte colony-stimulating factor. Mol Cell Biol 12:183-189, 1992.
PubMed
7) Tanaka T, et al:Evi-1 raises AP-1 activity and stimulates c-fos promoter transactivation with dependence on the second zinc finger domain. J Biol Chem 269:24020-24026, 1994.
 
8) Kurokawa M, et al:The oncoprotein Evi-1 represses TGFβ signalling by inhibiting Smad3. Nature 394:92-94, 1998.
 
9) Kurokawa M, et al:The Evi-1 oncoprotein inhibits c-Jun N-terminal kinase and prevents stress-induced cell death. EMBO J 19:2958-2968, 2000.
 
10) Morishita K, et al:Activation of EVI-1 gene expression in human acute myelogenous leukemias by translocations spanning 300-400 kilobases on chromosome band 3q26. Proc Natl Acad Sci USA 89:3937-3941, 1992.
PubMed
11) Ohyashiki J H, et al:Ecotropic virus integration site-1 gene preferentially expressed in post-myelodysplasia acute myeloid leukemia possible association with GATA-1, GATA-2, and stem cell leukemia gene expression. Blood 12:3713-3718, 1995.
PubMed
12) Russell M, et al:Expression of EVII in myelodysplastic syndromes and other hematolgic malignancies without 3q26 translocations. Blood 84:1243-1248, 1994.
 
13) Imai Y, et al:Mutations of the AMLI gene in myelodysplastic syndrome anf their functional implications in leukemogenesis. Blood 96:3154-3150, 2000.
 
14) Uchida T, et al:Hypermethylation of the p15INK4B gene in myelodysplastic syndromes. Blood 90:1403-1409, 1997.
PubMed
15) Levine A J, et al:The p53 tumor suppressor gene. Nature 351:453-456, 1991.
PubMed
16) Hollstein M, et al:p53 mutations in human cancers. Science 253:49-53, 1991.
PubMed
17) Sugimoto K, et al:Mutations of the p53 gene in lymphoid leukemia Blood 77:1153-1156, 1991.
PubMed
18) Adamson D J, et al:P53 mutation in the myelodysplastic syndromes. Br J Haematol 89:61-66, 1995.
PubMed
P.64 掲載の参考文献
1) Toyama K, et al:Clinical implications of chromosomal abnormalities in 401 patients with myelodysplastic syndromes:amulticentric study in Japan. Leukemia 7:499-508, 1993.
 
2) Mufti G:Treatment strategies for myelodys-plastic syndromes. International Journal of Clinical Hematology 44:635, 2003.
 
3) Balman A, et al:Cencer genetics:from Boveri and Mendel to microarrays. Nature Rev 1:77-82, 2001.
 
4) Wunderlich V:V. JMM-past and present Chromosomes and cancer:Theodor Boveri's predictions 100 years later. J Mol Med 80:545-548, 2002.
 
5) De Lange T:Protection of mammalian telomeres. Oncogene 21:532-540, 2002.
PubMed
6) Kyo S, et al:Complex regulatory mechanisms of telomerase activity in normal and cancer cells:how can we apply them for cancer therapy? Oncogene 21:688-697, 2002.
PubMed
7) Hackett J A, et al:Balancing instability:dual roles for telomerase and telomere dysfunction in tumorigenesis. Oncogene 21:619-626, 2002.
PubMed
8) Ball S E, et al:Progressive telomere shortening in a plastic anemia. Blood 91:3582-3592, 1998.
 
9) Li X, et al:Abnormal telomere metabolism in Fanconi's anaemia correlates with genomic instability and the probability of developing severe aplastic anaemia. Br J Haematol 120:836-845, 2003.
 
10) Karadimitris A:Severe telomere shortening in patients with paroxysmal nocturnal hemoglobinuria affects both GPI-and GPI+ hematopoiesis. Blood 102(2):514-516, 2003.
PubMed
11) Allosopp R C, et al Replicative senescence of hematopoietic stem cells during serial transh plantation:does telomere shortening play a role? Oncogene 21:3270-3273, 2002.
 
12) Mitchell J R, et al:A telomerase component is defective in the human disease dyskeratosis congenita. Nature 402:551-555, 1999.
PubMed
13) Li X, et al:Abnormal telomere metabolism in Fanconi's anaemia correlates with genomic instability and the probability of developing severe aplastic anaemia Br J Haematol 120:836-845, 2003.
 
14) Vulliamy T, et al:Association between aplastic anaemia and mutations in telomeraseRNA. Lancet 22:2168-2170, 2002.
 
15) Ohyashiki J H, et al:Telomere shortening associated with disease evolution patterns in myelodysplastic syndromes. Cancer Res 54:3557-3560, 1994.
PubMed
16) Ohyashiki J H, et al:Telomere stability is frequently impaired in high-risk groups of patients with myelodysplastic syndromes. Clin Cancer Res 5(5):1155-1160, 1999.
PubMed
17) Ohyashiki J H, et al:Telomeres and telomerase in hematologic neoplasia. Oncogene 21:680-687, 2002.
PubMed
18) Sashida G, et al:Telomere dynamics in myelodysplastic syndrome determined by telomere measurement of marrow metaphases. Clin Cancer Res 9:1489-1496, 2003.
PubMed
P.74 掲載の参考文献
1) Bennett J M, et al:Proposals for the classification of the myelodysplastic syndrome. Br J Haematol 51:189-199, 1982.
PubMed
2) Yoshida Y:Hypothesis. Apotosis may be the mechanism responsible for the premature intramedullary cell death in myelodysplastic syndrome. Leukemia 7:144-146, 1993.
 
3) Kerr J, et al:Apoptosis:abasic biological phenomenon with wide-ranging implications in tissue kinetics. Br J cancer 26:239-257, 1972.
 
4) Thompson C B, et al::Apoptosis in the patho-genesis and treatment of disease. Science 267:1456-1462, 1995.
 
5) Clark D M, et al:Apoptosis is a common histopathological finding in myelodysplasia. The correlate of ineffective hematopoiesis. Leuk Lymphoma 2:415-418, 1990.
PubMed
6) Bogdanovic A D, et al:Incidence and apoptosis in myelodysplastic syndrome. Morphological and ultrastructural assessment. Leukemia 11:656-659, 1997.
PubMed
7) Raza A, et al:Apoptosis in bone marrow biopsy samples involving stromal and hematolpoietic cells in 50 patients with myelodysplastic syndromes. Blood 86:268-276, 1995.
PubMed
8) Lepelley P, et al:Is apoptosis a massive process in myelodysplastic syndrome? Br J Haematol 95:368-371, 1996.
PubMed
9) Gersuk G, et al:Fas(CD95) receptor and Fay Ugand expression in bone marrow cells from patients with myelodysplastic syndrome. Blood 88:1122-1123, 1996.
 
10) Kawabata H, et al:High levels of Ca2+-in-dependent endonuclease activity capable of producing nucleosomal-size DNA fragmentation in non-adherent marrow mononuclearcels from patients with myelodysplastic syndromes and acute myelogenous leukemia. Leukemia 10:67-73, 1996.
PubMed
11) Raza A, et al:Novel insights in the biopsy of myelodysplastic syndromes, Excessive apoptosis and role of cytokines. Int J Hematol 63:265-278, 1996.
PubMed
12) Anna Jonasova, et al:Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anemias without hypoplastic bone marrow. Br J Haematol 100:304-309, 1998.
 
13) Rajapaska R, et al:Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells. Blood 88:4275-4287, 1997.
 
14) Parker J E, et al:Low risk myelodysplastic synfrome is associated with excessive apoptosis and increased ratio of pro-versus anti-apoptotic bcl-2-related protein. Br J Haematol 103:1075-1082, 1998.
PubMed
15) Parker J E, et al:The role of apoptosis, proliferation and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS. Blood 96:3932-3938, 2000.
PubMed
16) Oyake T, et al:ASH, annual meeting 2000, in San-Fransisco, USA. Abstract#1548.
 
P.81 掲載の参考文献
1) Young N S:Myelodysplastic Syndrome. II. Role of the Immune system in the pancytopenia of MDS and Immunosuppressive therapies. Hematology 2002, American Socieity of Hematology Education Program Book, pp146-150.
 
2) Barrett A J, et al:Achievements in understanding and treatment of myelodysplastic syndromes. II. Immune mechanisms and modulation in MDS. Hematology 2000, American Socieity of Hematology Education Program Book, pp117-122.
 
3) Kitagawa M, et al:0verexpression of tumor necrosis factor(TNF)-alpaha and interferon(IFN)-gamma by bone marrow cells from patients with myelodysplastic syndromes. Leukemia 11:2049-2054, 1997,
 
4) Gersuk G M, et al:A role for tumour necrosis factor-alpha:Fas and Fas-ligand in marrow failure associated with myelodysplastic syndorome. Br J Haematol 103:176-188, 1998.
 
5) Allampallam K, et al:Biological significance of proliferation, apoptosis, cytokines, and monocyte/macrophage cells in bone marrow biposies of 145 patients with myelodysplastic syndrome. Int J Hematol 75:289-297, 2002.
 
6) Molldrem J, et al:Haematological response of patients with myelodysplastic syndrome to antihymocyte globulin is associated with a loss of lymphocytemediated inhibition of CFU-GM and alterations in T-cell receptor Vbeta profiles. Br J Haematol 28:148-155, 2000.
 
7) Kitagawa M, et al:Localization of Fas and Fas ligand in bone marrow cells demonstrat-ing myelodysplasia. Leukemia 12:486-492, 1998.
 
8) Fontenay-Roupie M, et al:ineffective erythropoiesis in myelodysplastic syndromes:cor-relation with Fas expression but not with lack of erythropoietin receptor signal transduction. Br J Haematol 106:464-473, 1999.
 
9) Bouscary D, et al:Fas/Apo-1(CD95) expression and apoptosis in patients with myelodysplastic syndromes. Leukemia 11:839-845, 1997.
PubMed
10) Harada H, et al:Implications of somatic mutation in the AMLI gene in radiation-associated and therapy-related myelodys-plastic syndome/acute myeloid leukemia. Blood 10l:673-680, 2003.
 
11) Harada H, et al:High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodys-plasia Emphasis on mutations in the carboxy-terminal region. Blood(in press)
 
12) 木村昭郎, 他:骨髄異形成症候群の骨髄CD34陽性細胞における接着因子発現の検討. 厚生省特定疾患「血液系疾患調査研究班特発性造血障害分科会」平成10年度研究業績報告書, p61-62, 1999.
 
13) Pruneri G, et al:Angiogenesis in myelodys-plastic syndromes. Br J Cancer 81:1398-1401, 1999.
 
14) Sultana T A et al:Expression and functional analysis of granulocyte colon-stimulating factor on CD34++cells in patients with MDS and MDS-AML Br J Haematol 121:63-75, 2003.
 
P.90 掲載の参考文献
1) Enright H, et al:Paraneoplastic autoimmune phenomena in patients with myelodysplastic syndromes:response to immunosuppressive therapy. Br J Haematol 91:403-408, 1995.
PubMed
2) Okamoto T, et al:Correlation between immunological abnormalities and prognosis in myelodysplastic syndrome patients. Int J Hematol 66:345-351, 1997.
PubMed
3) Saif M W, et al:Autoimmune phenomena in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia. Leuk Lymphoma 43:2083-2092, 2002,
PubMed
4) Novaretti M C, et al:Immunohematological findings in myelodysplastic syndrome. Acta Haematol 105:1-6, 2001.
PubMed
5) Anderson R W, et al:Lymphocyte abnormalities in preleukemia-I. Decreased NK activity, anomalous immunoregulatory cell subsets and deficient EBV receptors. Leuk Res 7:389-395, 1983.
PubMed
6) Tefferi A, et al:Chronic myelomonocytic leukemia:natural history and prognostic determinants. Mayo Clin Proc 64:1246-1254, 1989.
PubMed
7) Nishie W, et al:Sweet's syndrome evolved from recurrent erythema nodosum in a patient with myelodysplastic syndrome. J Dermatol 29:91-95, 2002.
 
8) Espinosa G, et al:Myelodysplastic and myeloproliferative syndromes associated with giant cell arteritis and polymyalgia rheumatica:a coincidental coexistence or a causal relationship? Clin Rheumatol 21:309-313, 2002.
PubMed
9) Castro M, et al:Rheumatic manifestations in myelodysplastic syndromes. J Rheumatol 18:721-727, 1991,
PubMed
10) Van Rhee F, et al:Coombs negative haemolytic anaemia responding to intravenous immunoglobulins in a patient with myelodysplastic syndrome. Clin Lab Haematol 13:99-101, 1991.
 
11) Tamura S, et al:[Coombs negative auto-immune hemolytic anemia in a patient with myelodysplastic syndrome]. Rinsho Ketsueki 32:132-136, 1991.
 
12) Drabick J J, et al:Concurrent pernicious anemia and myelodysplastic syndrome. Ann Hematol 80:243-245, 2001.
PubMed
13) Tsukamoto N, et al:Clonality in myelodysplastic syndromes:demonstration of pluripotent stem cell origin using X-linked restriction fragment length polymorphisms. Br J Haematol 83:589-594, 1993.
PubMed
14) Vollmer M, et al:Expression of human leucocyte antigens and co-stimulatory molecules on blasts of patients with acute myeloid leukaemia. Br J Haematol 120:1000-1008, 2003.
PubMed
15) Molnar L, et al:Detection of TNFalpha expression in the bone marrow and determination of TNFalpha production of peripheral blood mononuclear cells in myelodysplastic syndrome. Pathol Oncol Res 6:18-23, 2000.
PubMed
16) Green A R et al:Cutaneous vasculitis in patients with myelodysplasia. Br J Haematol 74:364-365, 1990.
PubMed
17) George S W, et al:Seronegative inflammatory arthritis in the myelodysplastic syndromes. Semin Arthritis Rheum 21:345-354, 1992.
PubMed
18) Miescher P A, et al:Autoimmune myelodysplasias. Semin Hematol 28:322-330, 1991.
PubMed
19) Wang H, et al:Clinical significance of a minor population of paroxysmal nocturnal hemoglobinuriatype cells in bone marrow failure syndrome. Blood 100:3897-3902, 2002.
PubMed
20) Epperson D E, et al:Oligoclonal T cell expansion in myelodysplastic syndrome:evidence for an autoimmune process. Leuk Res 25:1075-1083, 2001.
PubMed

第3章 骨髄異形成症候群の診断

P.100 掲載の参考文献
1) Bennett J M et al:Proposal for the classification of the acute leukaemias. Br J Haematol 33:451-458, 1976.
 
2) Bennett J M, et al:Proposals for the classification of myelodysplastic syndromes. Br J Haematol 51:189-199, 1982.
PubMed
3) Harris N L et al:World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues:report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 17:3835-3849, 1999.
PubMed
4) Brunning R D, et al:Myelodysplastic syndromes. In:Pathology and Genetics of Tumors of Haematopoietic and Lymphoid Tissues(Jaffe E S, et al eds), p61-74 IARC Press, Lyon, 2001.
 
5) Vardiman J W, et al:The World Health Organizadon(WHO) classification of the myeloid neoplasms. Blood 100:2292-2302, 2002.
PubMed
6) Bain BJ:Morphology of blood cells. In:Blood cells. A practical guide.(Bain B J, ed), p52-154. Blackwell Science, Oxford, 2002
 
7) Germing U et al:Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes:aretrospective analysis of 1600 patients Leuk Res 24:983-992, 2000.
 
8) Nosslinger T, et al:Myelodysplastic syndromes, from French-American-British to World Health Organization:comparison of classifications on 431 unselected patients from a single institution. Blood 98:2935-2941, 2001.
PubMed
9) Bennett J M:The World Health Organization(WHO) classification of acute leukemias and the myelodysplastic syndromes. Int J Hematol 72:131-133, 2000.
PubMed
10) Bennett J M, et al:Myelodysplastic syndromes:from French-American-British to World Health Organization:a commentary. Blood 99:3074-3075, 2002.
PubMed
11) Kuriyama K, et al:Diagnostic signficance of detecting pseudo-Pelger-Huet anomalies and micro-megakaryocytes in myelodysplastic syndrome. Br J Haematol 63:665-669, 1986.
 
12) Bain B J:Myelodysplastic syndromes. In:Leukemia diagnosis.(Bain B J, ed), p113-142. Blackwell Science, Oxford, 1999.
 
13) Hamblin T J, et al:Myelodysplastic disorders In:Blood and bone marrow pathology.(Wick-ramasinghe S N, et al, eds), p331-350. Churchill Livingstone, London, 2003.
 
P.108 掲載の参考文献
1) 吉田弥太郎, 他:不応性貧血(骨髄異形成症候群)の診断基準案について. 厚生省特定疾患血液系疾患調査研究班・特発性造血障害分科会平成8年度研究業績報告書:31-33, 1997.
 
2) 吉田弥太郎, 他:1997年度不応性貧血全国実態調査. 厚生省特定疾患血液系疾患調査研究班・特発性造血障害分科会平成9年度研究業績報告書:29-30, 1998.
 
3) Greenberg P, et al:International scoring system for evaluating Prognosis in myelodysplastic syndromes. Blood 89:2079-2088, 1997.
PubMed
4) Bennett J M, et al:Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51:189-199, 1982.
PubMed
5) Brunning R D, et al:Myelodysplastic syndromes. World Health Organization classification of tumours:pathology and genetics of tumours of haematopoietic and lymphoid tissues(edited by Jaffe E S, et al), p61-73. IARC Press, Lyon, 2001.
 
6) 通山薫, 他:MDS長期生存例の調査. 厚生科学研究・特発性造血障害に関する研究班平成11年度研究業績報告書:72-73, 2000.
 
7) Mufti G J, et al:Immunological abnormalities in myelodysplastic syndromes Br J Haematol 63:143-147, 1986.
PubMed
8) Wang H, et al:Clinical signficance of a minor population of paroxysmal nocturnal hemoglobinuriatype cells in bone marrow failure syndrome. Blood 100:3897-3902, 2002.
 
9) Ogata K, et al:Clinical significance of phenotypic features of blasts in patients with myelodysplastic syndrome. Blood 100:3887-3896, 2002.
PubMed
10) Saunthararajah Y, et al:HLA-DR15(DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. Blood 100:1570-1574, 2002.
PubMed
P.114 掲載の参考文献
1) Kusumoto S, et al:Bone marrow patterns in patients with aplastic anemia and myelodysplastic syndrome:observations with magnetic resonance imaging. Eur J Haematol 59:155-161, 1997.
PubMed
2) Nagai K, et al The Myelodysplastic syndromes, Pathobiology and Clinical Management (John M. Bennet 監修), p121-138. Marcel Dekker, Inc. New York, 2002.
 
3) Takagi S, et al:Prognostic Significance of Magnetic Resonance Imaging of Femoral Marrow in Patients With Myelodysplastic Syndromes. J Clin Oncol 17:277-283, 1999.
PubMed
4) Lorand-Metze I, et al:Magnetic Resonance Imaging of Femoral Marrow Cellularity in Hypocellular Haemapoietic Disorders. Clin Radiol 56:107-110, 2001.
 
5) Greenberg P, et al:International scoring sys-tem for evaluating Prognosis in myelodysplastic syndromes. Blood 89:2079-2088, 1997.
 
P.119 掲載の参考文献
1) Bennett J M, et al:Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51:189-199, 1982.
PubMed
2) 吉田彌太郎:MDSの臨床-骨髄異形成症候群-. 新興医学出版社, 東京, 1991.
 
3) Bennett J M et al:Proposals for the classification of the acute leukaemias. Br J Haematol 33:451-458, 1976.
PubMed
4) 内野治人, 他:不応性貧血の診断基準. 厚生省特定疾患特発性造血障害調査研究班 昭和59年度研究業績報告書, p221-226, 1985.
 
5) 内野治人, 他:不応性貧血の診断基準の提唱. 臨血 27:36-42, 1986.
 
6) Jaffe E S, et al:Pathology and genetics of tumours of haematopoietic and lymphoid tissues. IARC Press, Lyon, 2001.
 
7) Bennett J M:World Health Organization classification of the acute leukemias and myelodysplastic syndrome. Int J Hematol 72:131-133, 2000.
PubMed
P.127 掲載の参考文献
1) 吉田弥太郎:MDSの臨床, p79-80 新興医学出版社, 東京, 1999.
 
2) Benett J M, et ak Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51:189-199, 1982.
 
3) Brunning R D, et al:In:Tumors of Haematopoietic and Lymphoid Tissues World Health Organization Classification of Tumors, p63-73, IRAC Press, Lyon, Washington, 2001.
 
4) Felman P, et al:The syndrome of abnomal chromatin clumping in leucocytes:A myelodysplastic disorder with proliferative features? Br J Haematol 70:49-54, 1988.
 
5) Tricot G, et al:Bone marrow histology in myelodysplastic syndromes:I. Histological findings in myelodysplastic syndromes and comparison with bone marrow smears. Br J Haematol 57:423-430, 1984.
PubMed
6) J. W. Choi, et al:Significance of fetal hemoglobin-containing erythroblasts(F blasts) and the F blast/F cell ratio in myelodysplastic syndromes Leukemia 16:1478-1483, 2002.
 
7) Stetler-Stevenson M, et al:Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome. Blood 98:979-987, 2001.
PubMed
8) Ogata K, et al:Clinical significance of phenotypic features of blasts in patients with myelodysplastic syndrome. Blood 100:3887-3896, 2002.
PubMed
9) Vallespi, et al:Diagnosis, classification, and cytogenetics of myelodysplastic syndromes. Haematologica 83:258-275, 1998.
PubMed
10) Olney J H, et al:In:the Myelodysplastic syndrome(Bennett J M, ed), p89-110. Marcel Dekker, Inc. New York, 2002.
 
11) Kakazu N, et al:Combined spectral karyotyping and DAPI banding analysis of chromosome abnormalities in myelodysplastic syndrome. Genes Chromosomes Cancer 26:336-345, 1999.
PubMed
12) Tuzuner N, et al:Hypocellular myelodysplastic syndromes(MDS):New proposal & Br J Haematol 91:612-617, 1995.
 
13) Tomonaga M, et al:In:the Myelodysplastic syndrome(Bennett J M, ed), p121-135. Marcel Dekker, Inc. New York, 2002.
 
14) Sultan C, et al:Acute myelodysplasia with myelofibrosis:Areport of eight case & Br J Haematol 49:11-16, 1981.
 

第4章 骨髄異形成症候群の管理・治療

P.136 掲載の参考文献
1) Hughes W T, et al:2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34:730-751, 2002
PubMed
2) Greenberg P, et al:International scoring system for evaluating Prognosis in myelodysplastic syndromes. Blood 89:2079-2088, 1997.
PubMed
3) Bowen D, et al:Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. Br J Haematol 120:187-200, 2003.
PubMed
4) Raad II, et al:Treatment of febrile neutropenic patients with cancer who require hospitalization:a prospective randomized study comparing imipenem and cefepime. Cancer 98:1039-1047, 2003.
PubMed
5) Mermel LA, et al:Guidelines for the management of intravascular catheter-related infections. Clin Infect Dis 32:1249-1272, 2001.
PubMed
6) Heussel C P, et al:Pneumonia in febrile neutropenic patients and in bone marrow and blood stem-cell transplant recipients:use of high-resolution computed tomography. JCIin Oncol 17:796-805, 1999.
PubMed
7) Enright H, et al:Autoimmune phenomena in patients with myelodysplastic syndromes. Leuk Lymphoma 24:483-489, 1997.
PubMed
8) Freifeld A, et al:A double-blind compari-son of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. N Engl J Med 341:305-311, 1999.
 
9) Kern W V, et al:Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med 341:312-318, 1999.
PubMed
10) Rex J H, et al:Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America. Clin Infect Dis 30:662-678, 2000.
 
11) Ozer H, et al:2000 update of recommendations for the use of hematopoietic colony-stimulating factors:evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol 18:3558-3585, 2000.
 
12) Negrin RS, et al:Maintenance treatment of patients with myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor. Blood 76:36-43, 1990.
PubMed
13) Negrin R S, et al:Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin:evidence for in vivo synergy. Blood 87:4076-4081, 1996.
PubMed
P.144 掲載の参考文献
1) Boultwood J, et al:Clonality in the myelodysplastic syndromes. Int J Hematol 73(4):411-415, 1992.
 
2) Anderson J E:Bone marrow transplantation for myelodysplasia. Blood Rev 14:63-77, 2000.
PubMed
3) de Witte T, et al:Hematopoietic stem cell transplantation for patient with myelodysplastic syndromes and secondary acute myeloid leukemias:areport on behalf of the European Group for Blood and Marrow Transplantation(EBMT). Br J Haematol 110:620-630, 2000.
 
4) Castro-Malaspina H, et al:Unrelated donor marrow transplantation for myelodysplastic syndromes:outcome analysis in 510 trans-plants facilitated by the National Marrow Donor Program Blood 99:1943-1951, 2002.
 
5) 吉田弥太郎:MDSの概念改訂. MDSの臨牀状 p1-16 新興医学出版社, 東京, 1999.
 
6) Mcfarland J C:Alloimmunization and plate-let transfusion. Semin Hematol 33:315-328, 1996.
 
7) 上田恭典:血液製剤の使用状況の分析ならびに需給に関する研究. 血液製剤の使用状況の分析ならびに需給に関する研究平成11年度報告書. 清水勝. p193-229, 2000.
 
8) 加藤淳二:輸血による鉄過剰症の予防と治療は? EBM血液疾患の治療 (押味和夫他編) p624-630. 中外医学社, 東京, 2002.
 
9) Kushner J P, et al:Secondary iron overload. Hematology (Am Soc Hematol Educ Pro-gram) 47-61, 2001.
 
10) 徐 岩文, 他:免疫学的副作用とその防止. 輸血学理論と展望 (池田久實他編), p172-182. 北海道大学図書刊行会, 札幌, 2000.
 
11) Oliviery N E et al:Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med 331:574-578, 1994.
 
12) Hall A G, et al:lncreased platelet associated immunoglobulin in myelodysplastic syndromes. Br J Haematol 65:245-246, 1987.
 
13) Slichter S J, et al:Thrombocytopenia Mechanisms and Management of defects in platelet production. Clin Haematol 7:523-539, 1978.
PubMed
14) 血小板製剤の使用基準. 血液製剤の使用にあたって (血液製剤調査機構編), p23-32. 薬業事報社, 東京, 1999.
 
15) Sagmeister M, et al:A restrictive platelet transfusion policy allowing long-term support of outpatients with severe aplastic anemia. Blood 93:9124-3136, 1999.
 
16) 半田 誠:血液疾患患者に対する血小板輸血の使用基準. 医学のあゆみ 205(5):355-359, 2003.
Medical*Online
17) Schiffer C A, et al:Platelet transfusion for patients with cancer. clinical practice guidelines of the American Society of Clinical Oncology. J ClinOncol 19:1519-1538, 2001.
 
18) Zumberg M S, et al:Aprospective randomized trial of prophylactic platelet transfusion and bleeding incidence in hematopoietic stemcell transplant recipients:10000/L versus 20000/microl trigger. Biol Blood Marrow Transplant 8:569-576, 2002.
 
19) American Society of Clinical Oncology:2000 update of recommendations for the use of hematopoietic colony-stimulating factors:Evidence-based, clinical practice guidelines. J Clin Oncol 18:3558-3585, 2000.
 
20) 佐分利能生他:G-CSFの間欠投与が感染予防に有効であったと考えられる骨髄異形性症候群 (RAEB) の1例. 感染症誌 70:506-511, 1996.
 
P.154 掲載の参考文献
1) Shimamoto T, et al:Immunosuppressive therapy for myelodysplastic syndromes. Leuk Lymphoma 44:593-604, 2003.
PubMed
2) Tichelli A, et al:Antilymphocyte globulin for myelodysplastic syndrome. Br J Haematol 68:139-140, 1988.
PubMed
3) Biesma D H, et al:immunosuppressive therapy for hypoplastic myelodysplastic syndrome. Cancer 79:1548-1551, 1997.
PubMed
4) Molldrem J J, et al:Anti-thymocyte globulin for patients with myelodysplastic syndrome. Br J Haematol 99:699-705, 1997.
PubMed
5) Jonasova A, et al:Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow. Br J Haematol 100:304-309, 1998.
PubMed
6) Bagby C G:Mechanism of glucocorticoid activity inpatients with the preleukemic syndrome(hemopoietic dysplasia). Leuk Res 4:571-580, 1980.
 
7) Motoji T, et al:Successful treatment of refractory anemia with high-dose methylprednisolone. Am J Hematol 33:8-12, 1990.
PubMed
8) Sauthararajah Y, et al:HLA-DR15(DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. Blood 100:1570-1574, 2002.
 
9) Shimamoto T, et al:Cyclosporin A therapy for patients with myelodysplastic syndrome:multicenter pilot studies in Japan. Leuk Res 27:783-788, 2003.
PubMed
10) Cheson B D, et al:Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 96:3671-3674, 2000.
 
11) 松田晃, 他:WHO分類のRefractory anemia (RA)とRefractory cytopenia with multilineage dysplasia(RCMD), および日独症例の比較.第65回日本血液学会総会, 第45回日本臨床血液学会総会, 学会シンポジウム, 2003.
 
12) Shimamoto T, et al:Successful treatment with cyclosporine A for myelodysplastic syndrome with erythroid hypoplasia associated with T-cell receptor gene rearrange-ments. Br J Haematol 114:358-361, 2001.
 
13) Epperson D E, et al:Oligoclonal T cell expansion in myelodysplastic syndrome:evidence for an autoimmune process. Leuk Res 25:1075-1083, 2001.
PubMed
14) Matsutani T, et al:Determination of T-cell receptors of clonal CD8-positive T-cells in myelodysplastic syndrome with erythroid hypoplasia. Leuk Res 27:305-312, 2003.
PubMed
15) Nakao S, et al:Identification of a specific HLA class II haplotype strongly associated with susceptibility to cyclosporine-dependent aplastic anemia. Blood 84:4257-4261, 1994.
PubMed
16) Dunn D E, et al:Paroxymal nocturnal hemoglobinuria cells in patients with bone marrow failure syndromes. Ann Intern Med 131:401-405, 1999.
 
17) 中尾眞二:骨髄不全におけるPNH血球の増加と臨床的意義. 血液フロンティア 12:1059-1067, 2002.
 
P.162 掲載の参考文献
1) Bessho M, et al:Improvement of anemia by recombinant erythropoietin in patients with myelodysplastic syndromes and aplastic anemia. Int J Cell Cloning 8:445-458, 1990.
PubMed
2) Italian cooperative study group for rHuEpo in myelodysplastic syndromes:a randomized double-blind placebo-controlled study with subcutaneous recombinant human erythro-poietin in patients with low-risk myelodysplastic syndromes. Br J Haematol 403:1070-1074, 1998.
 
3) Bessho M, et al:Trilineage recovery by combination therapy with recombinant human granulocyte colony-stimulating factor and erythropoietin in patients with aplastic anemia and refractory anemia. Stem Cells 12:604-615, 1994.
PubMed
4) Matsuda A, et al:Long-term follow-up of patients with aplastic anemia and refractory anemia responding to combination therapy with recombinant human granulocyte colony-stimulating factor and erythropoietin. Int J Hematol 76:244-250, 2002.
PubMed
5) Hellstrom-Lindberg E, et al:Erythroid response to treatment with G-CSF pluserythropoietin for the anemia of patients with myelodysplastic syndromes:proposal for a predictive model. Br J Haematol 99:344-351, 1997.
 
6) Hellstrom-Lindberg E, et al:A validated decision model for treating the anemia of myelodysplastic syndromes with erythropoietin+granulocyte colony-stimulating factor:significant effects on quality of life. Br J Haematol 120:1037-1046, 2003.
PubMed
7) Miller A M, et al:Limited erythropoietic response to combined treatment with recombinant human interleukin-3 and erythropoietin in myelodysplastic syndromes. Leuk Res 23:77-83, 1999.
PubMed
8) Thompson J A, et al:Effect of recombinant human erythropoietin combined with granulocyte/macrophage colony-stimulating factor in the treatment of patients with myelodysplastic syndrome. Blood 95:1175-1179, 2000.
PubMed
9) Bowen D, et al:Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. Br J Haematol 120:187-200, 2003.
PubMed
10) Rizzo J D, et al:Use of epoetin in patients with cancer:evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood 100:2303-2320, 2002.
 
11) Casadevall N, et al:Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 346:469-475, 2002.
PubMed
12) http://www.jnj.com/
 
13) Giraudier S, et al:EPO-antibodies induced erythroblastopenia in MDS:two cases with either alpha or beta recombinant erythropoietin. Leuk Res 27(suppl 1):S99, 2003.
 
14) Ozer H, et al:2000 update of recommendations for the use of hemtopoietic colonystimulating factors:evidence-based, clinical practice guidelines. J Clin Oncol 18:3558-3585, 2000
 
P.169 掲載の参考文献
1) Najean Y, et al:Refractory anemia with excess of myeloblasts in the bone marrow:a clinical trial of androgens in 90 patients. Br J Haematol 37:25-33, 1977.
PubMed
2) Najean Y, et al:Refractory anemia with excess of blast cells:prognostic factors and effect of treatment with androgens of cytosine arabinoside. Cancer 4:1976-1982, 1979.
 
3) Locker D:Treatment of refratory anemias with methenolone. Acta Med Scand 205:97-101, 1979.
 
4) 桜田恵右, 他前白血病状態の治療. 癌と化療 15(6):1960-1967, 1988.
 
5) Kobaba R, et al:Androgen in the treatment of refractory anemia. Int J Hemaotol 54:103-107, 1991.
 
6) Letendre L, et al:Myelodysplastic syndrome treatment with danazol and cisretinotic acid. Am J Hematol 48:233-236, 1995.
PubMed
7) Bagby G C, et al:Glucocorticoid therapy in the preleukemic syndrome (Hemopoietic dysplasia). Ann Intern Med 92:55-58, 1980.
PubMed
8) Motoji T, et al:Successful treatment of refractory anemia with high-dose methylpredonisolone. Am J Hematol 33:8-12, 1990.
 
9) Motomura S, et al:Successful treatment of refratory anemia by high-dose methylpredonisorone associated with an increment in CD68-positive cells in bone marrow. Am J Hematol 66:80-84, 2001.
 
10) Kitagawa M, et al:Overexpression of tumor necrosis factor (TNF)-α and interferon (IFN)-γ by bone marrow cells from patients with myelodysplastic syndromes. Leukemia 11:2049-2054, 1997.
 
11) Verhoef G E G, et al:Measurement of serum cytokine levels in patients with myelodysplastic syndromes. Leukemia 6:1268-1272, 1992.
PubMed
12) Raza A, et al:Novel insights into the biology of myelodysplastic syndromes:excessive apoptosis and the role of cytokines. Int J Hematol 63:265-278, 1996.
PubMed
13) Imai Y, et al:Sustained trilineage recovery and disappearance of abnormal chromosome clone in a patient with myelodysplastic syndrome following combination therapy with cytokines and high-dose methlpredonizolone. Br J Haematol 93:146-150, 1996.
 
P.182 掲載の参考文献
1) Allampallam K, et al:Cytokines and MDS. Cancer Treat Res 108(2):93-100, 2001.
 
2) Stasi R, et al:Infiiximab chimaeric anti-tumour necrosis factor alpha monoclonal antibody treatment for patients with myelodysplastic syndromes. Br J Haematol 116(2):334-337, 2002.
 
3) Deeg H J, et al:Soluble TNF receptor fusion protein (etanercept) for the treatment of myelodysplastic syndrome:apilot study. Leukemia 16(2):162-164, 2002.
 
4) Rosenfeld C, et al:Pilot study of recombinant human soluble tumor necrosis factor receptor (TNFR:Fc) in patients with low risk myelodysplastic syndrome. Leuk Res 26(8):721-724, 2002.
PubMed
5) Maciejewski J p, et al:A pilot study of the recombinant soluble human tumour necrosis factor receptor (p75)-Fc fusion protein in patients with myelodysplastic syndrome. Br J Haematol 117(1):119-126, 2002.
PubMed
6) Raza A, et al:Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood 98(4):958-965, 2001.
PubMed
7) Strupp C, et al:Thalidomide for the treatment of patients with myelodysplastic syndromes. Leukemia 16(1):1-6, 2002.
PubMed
8) Tsirigotis P, et al:Thalidomide in the treatment of myelodysplastic syndrome with fibrosis, Leuk Res 26(10):965-966, 2002.
PubMed
9) Badros A, et al:Thalidomide paradoxical effect on concomitant multiple myeloma and myelodysplasia. Leuk Lymphoma 43(6):1267-1271, 2002.
PubMed
10) Richardson P G, et al:Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 100(9):3063-3067, 2002.
PubMed
11) List A F, et al:Stimulation of hematopoiesis by amifostine in patients with myelodysplastic syndrome. Blood 90(9):3364-3369, 1997.
PubMed
12) Grossi A, et al:Amifostine in the treatment of low-risk myelodysplastic syndromes. Haematologica 85(4):367-371, 2000.
PubMed
13) Hofmann W K, et al:Effect of treatment with amifostine used as a single agent in patients with refractory anemia on clinical outcome and serum tumor necrosis factor alpha levels. Ann Hematol 79(5):255-258, 2000.
PubMed
14) Kizaki K, et al:Differentiation-inducing agents in the treatment of myelodysplastic syndromes. Semin Oncol 19(1):95-105, 1995.
 
15) Yoshida Y, et al:A randomized study of alfacalcidol in the refractory myelodysplastic anaemias. A Japanese cooperative study. Int J Clin Pharmacol Res 13(1):21-27, 1993.
PubMed
16) Miyazawa K, et al:Vitamin K2 therapy for myelodysplastic syndromes(MDS) and post-MDS acute myeloid leukemia:information through a questionnaire survey of multicenter pilot studies in Japan. Leukemia 14(6):1156-1157, 2000.
PubMed
17) Takami A, et al:Menatetrenone, a vitamin K2 analog, ameliorates cytopenia in patients with refractory anemia of myelodysplastic syndrome. Ann Hematol 81(1):16-19, 2002.
PubMed
18) Miyazawa K, et al:Apoptosis/differentiation-inducing effects of vitamin K20 on HL-60 cells:dichotomous nature of vitamin K2 in leukemia cells. Leukemia 15(7):1111-1117, 2001.
 
19) Funato K, et al:Combination of 22-oxa-1, 25-dihydroxyvitamin D(3), a vitamin D(3) derivative, with vitamin K(2)(VK2) synergistically enhances cell differentiation butsuppresses VK2-inducing apoptosis in HL-60cells. Leukemia 16(8):1519-1527, 2002.
 
P.192 掲載の参考文献
1) Miller K B, et al:The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes:a phase III intergroup study. Ann Hematol 65:162, 1992.
PubMed
2) Guideline, Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. Br J Haematol 120:187, 2003.
PubMed
3) Alessandrino E P, et al:Evidence-and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the ltalian Society of Hematology. Haematologica 87:1286, 2002.
 
4) Beran M et al:High-dose chemotherapy in high-risk myelodysplastic syndrome, convariate-adjusted comparison of five regimens. Cancer 92:1999, 2001.
 
5) Aul C, et al:Treatment of advanced myelodysplastic syndromes:Trendtoward more aggressive chemotherapy? Blut 33(suppl):382, 1990.
 
6) De Witte T, et al:Intensive anti-leukemic treatment of patients with myelo dysplastic syndromes and secondary acute myelogenous leukemia. Cancer 66:831, 1990.
 
7) Fenaux P, et al:Prognostic factors in adult de novo myelodysplastic syndromes treated by intensive chemotherapy. Br J Haematol 77:497, 1991.
PubMed
8) Estey E H, et al:Idarubicin plus continuousinfusion high-dose cytarabine as treatment for patients with acute myelogenous leukemia or myelodysplastic syndrome. Semin Oncol 20(suppl 8):1, 1993.
 
9) Lepeney P, et al:Expression of the multidrug resistance P-glycoprotein and its relationship to hematological charac-teristics and response to treatment in myelodysplastic syndromes. Leukemia 8:998, 1994.
 
10) Knauf W U, et al:Combination of mitoxantrone and etoposide in the treatment of myelodysplastic syndromes transformed into acute myeloid leukemia. Leuk & Lymphoma 12:421, 1994.
PubMed
11) Parker J E, et al:Fludarabine, cytarabine, G-CSF and idarubicin(FLAG-IDA) for the treatment of poor-risk myelodysplastic syndromes and acute myeloid leukemia. Br J Haematol 99:939, 1997.
PubMed
12) Economopoulos T, et al:Treatment of high risk myelodysplastic syndromes with idarubicin and cytosine arabinoside supported bygranulocyte-macrophage colony-stimulating factor(GM-CSF). Leuk Res 20:385, 1996.
PubMed
13) Bernasconi C, et al:Raondomized clinical study comparing aggressive chemotherapy with or without G-CSF support for high-risk meylodysplastic syndromes or secondary acute myeloid leukemia evolving from MDS. Br J Haematol 102:678, 1998.
PubMed
14) Beran M, et al:Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia. J Clin Oncol 17:2819, 1999.
PubMed
15) Denzlinger C, et al:Low-dose melphalan induces favourable responses in elderly patients with high-risk myelodysplastic syndromes or secondary acute myeloid leukaemia. Br J Haematol 108:93, 2000.
PubMed
16) Manoharan A, et al:Flexible low-intensity combination chemotherapy for elderly patients with acute myeloid leukemia. Int J Hematol 75:519, 2002.
PubMed
17) Ribrag V, et al:Phase II trial of CPT-11 in myelodysplastyic syndromes with excess of marrow blasts. Leukemia 17:319, 2003.
PubMed
18) Okamoto T, et al:Combination chemotherapy with risk factor-adjusted dose attenuation for high-risk myelodysplastic syndrome and resulting leukemia in the multiceter study of the Japan Adult Leukemia Study Group(JALSG):results of an interim analysis. Int J Hematol 72:200, 2000.
 
19) 古沢新平, 他:CAG療法によるMDSおよびその白血病期の治療血腫瘍. 35:462, 1997.
 
P.200 掲載の参考文献
1) Hellstrom-Lindberg E. Treatment of adult myelodysplastic syndromes. Int J Hematol 70:141-154, 1999.
PubMed
2) Cheson B D:Standard and low-dose chemotherapy for the treatment of myelodysplastic syndromes. Leuk Res 22:S17-S21, 1998.
PubMed
3) Guideline, Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. Brit J Haematol 120:187-200, 2003.
 
4) Miller K B, et al:The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes:a phase-III intergroup study. Ann Hematol 65:162-168, 1992.
PubMed
5) Hellstrom-Lindberg E, et al:A predictive model for the clinical response to low dose ara-C:a study of 102 patients with myelodysplastic syndromes or acute leukaemia. Br J Haematol 81:503-511, 1992.
PubMed
6) 古沢新平, 他:CAG療法によるMDSおよびその白血病期の治療.血腫瘍 35:462-473, 1997.
 
7) 松田光弘, 他. 白血病・悪性リンパ腫治療プロトコール集改訂版 (大野竜三編), 4. 進行期骨髄異形成症候群. p.118-123. 医薬ジャーナル社, 東京, 2003.
 
8) Gerhartz H H et al:A randomized phase II study of low-dose cytosine arabinoside (LD-AraC) plus granulocyte-macrophage colony-stimulating factor (rhG-CSF) in myelodysoplastic syndrome (MDS) with a high risk of developing leukemia. Leukemia 8:16-23, 1994.
 
9) Gerhartz H H, et al:Randomized 3 armed phase III study of interleukin 3(IL-3), or granulocyte/macrophage colony-stimulating factor (GM-CSF) as an adjuvant to low doses of cytosine arabinoside (LD-ARAC) for the treatment of high-risk myelodysplastic syn-dromes (HR-MDS). Blood 88(Suppl l):580a 1996.
 
10) Im T, et al:Treatment with cytosine arabinoside and granulocyte colony-stimulating factor in patients with myelodysplastic syndrome and its leukemic phase. Int J Hematol 60:215-223, 1994.
PubMed
11) Fukuhara T, et al:Treatment with low-dose cytosine arabinoside followed by administration of macrophage colony-stimulating factor prolongs the survivial of patients with RAEB, RAEB-t, or leukemic phase myelo-dysplastic syndrome:Apilot study. Int J Hematol 71:366-371, 2000.
 
12) Santini V, et al:Differentiation therapy of myelodysplstic syndromes:fact of fiction? Br J Haematol 102:1124-1138, 1998.
PubMed
13) Venditti A, et al:A phase-II trial of all trans retinoic acid and low-dose cytosine arabinoside for the treatment of high-risk myelodysplastic syndromes. Ann Hematol 79:138-142, 2000.
PubMed
14) Wijermans P, et al:Low-dose 5-aza-2-de-oxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome:amulticenter phase II study in elderly patients. J Clin Oncol 18:956-962, 2000.
 
15) Omoto E, et al:Low-dose melphalan for treatment of high-risk myelodysplastic syndromes. Leukemia 10:609-614, 1996.
PubMed
16) Denzlinger C, et al:Low-dose melphalan induces favourable responses in elderly patinets with high-risk myelodysplastic syndromes or secondary acute myeloid leukemia. Br J Haematol 108:93-95, 2000.
PubMed
17) Shibuya T, et al:Treatment of myelodysplastic syndrome and atypical leukemia with low-dose aclarubicin. Leuk Res 14:161-167, 1990.
PubMed
18) Harada M, et al:A randomized phase II trial of low-dose aclarubicin vs very low-dose cytosine arabinoside for treatment of myelodysplastic syndromes. Leuk Res 17:629-632, 1993.
PubMed
19) Johnson E, et al:Successful oral chemotherapy with idarubicin in refractory anaemia with excess blasts. Eur J Haematol 39:278-281, 1987.
PubMed
20) Greenberg B R, et al:Treatment of myelodysplastic syndromes with daily oral idarubicin. A phase I-II study. Cancer 71:1989-1992, 1993.
PubMed
21) Kuhta S L et al:A combination chemotherapy with low doses of cytarabine and etoposide for high risk myelodysplastic syndromes and their leukemic stage. Cancer 78:422-426, 1996.
 
22) Wattel E, et al:A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia. Blood 88:2480-2487, 1996.
PubMed
23) Cheson B D, et al:Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 96:3671-3674, 2000.
 
P.207 掲載の参考文献
1) Beran M, et al:Hematologic response of four patlents with smouldering acute myelogenous leukemia to partially pure gamma interferon. Leukemia 1(1):52-57, 1987.
 
2) Maiolo A T, et al:Recombinant interferon as first-line therapy for high-risk myelodysplastic syndromes. Leukemia 4(7):480-485, 1990.
PubMed
3) Rowinsky E K, et al:Hexamethylene bisacetamide in myelodysplastic syndrome:effect of five-day exposure to maximal therapeutic concentrations. Leukemia 6(6):526-534, 1992.
PubMed
4) Andreeff M, et al:Hexamethylene bisacetamide in myelodysplastic syndrome and acute myelogenous leukemia:a phase II clinical trial with a differentiation-inducing agent Blood 80(10):2604-2609, 1992.
PubMed
5) Feldman E J, et al:Homoharringtonine in patients with myelodysplastic syndrome(MDS) and MDS evolving to acute myeloid leukemia. Leukemia 10(1):40-42, 1996.
PubMed
6) Jones P A, et al:Cellular differentiation, cytidine analogs and DNA methylation. Cell 20(1):85-93, 1980.
PubMed
7) Herman J G, et al:Hypermethylation-associated inactivation indicates a suppressor role for p15INK4B1. Cancer Res 56(4):722-727, 1996.
PubMed
8) Jones P A, et al:Cancer epigenetics cones of age. Nat Genet 21(2):163-167, 1999.
 
9) Christiansen D H, et al:Methylation of p15INK4B is a common, is associated with deletion of genes on chromosome arm 7q and predicts a poor prognosis in therapy-related myelodysplasia and acute myeloid leukemia. Leukemia 17(9):1813-1819, 2003.
PubMed
10) Fruhwald M C:DNA methylation patterns in cancer:novel prognostic indicators? Am J Pharmacogenomics 3(4):245-260, 2003.
PubMed
11) Silverman L R, et al:Randomized controlled trial of azacitidine in patients with the myelodysplastic syndromes:astudy of the cancer and leukemia group B. J Clin Oncol 20(10):2429-2440, 2002.
 
12) Kornblith A B, et al:lmpact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial:a cancer and leukemia group Bstudy. J Clin Oncol 20(10):2441-2451, 2002.
 
13) Wijermans P, et al:Low-dose 5-aza-2-deoxycitidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome:a multicenter phase II study in elderly patients. J Clin Oncol 18(5):956-962, 2000.
 
14) Daskalakis M, et al:Demethylation of a hypermethylated p15/INK4B gene in patients with myelodysplastic syndrome by 5-aza-2-deoxycitidine(decitabine) treatment. Blood 100(8):2957-2964, 2002.
 
15) Waxman S:Differentiation therapy in acute myelogenous leukemia(non-APL). Leukemia 14(3):491-496, 2000.
PubMed
16) Gore S D, et al:Improved hematopoiesis in patients with myelodysplastic syndromes(MDS) and acute myeloid leukemia(AML) following administration of the putative differentiating agent sodium phenylbutyrate(SPB). Blood 88(10):582a, 1996.
 
17) List A F, et al:Stimulation of hematopoiesis by amifostine in patients with myelodysplastic syndrome. Blood 90(9):3364-3369, 1997.
PubMed
18) Hofmann W K, et al:Effect of treatment with amifostine used as a single agent in patients with refractory anemia on clinical outcome and serum tumor necrosis factor alpha levels. Ann Hematol 79(5):255-258, 2000.
PubMed
19) Tefferi A, et al:Amifostine alone and in combination with erythropoietin for the treatment of favorable myelodysplastic syndrome. Leuk Res 25(2):183-185, 2001.
PubMed
20) Timonen T T, et al:Therapeutic effect of heme arginate in myelodysplastic syndromes. Eur J Haematol 49(5):234-238, 1992.
PubMed
21) Volin L, et al:Heme arginate treatment for myelodysplastic syndromes. Leuk Res 12(5):423-431, 1988.
PubMed
22) Collins S J:The role of retinoids and retinoic acid receptors in normal hematopoiesis. Leukemia 16(10):1896-1905, 2002.
PubMed
23) Breitman T R, et al:Induction of differentiation of the human promyelocytic leukemia cell line(HL-60) by retinoic acid. Proc Natl Acad Sci USA 77(5):2936-2940, 1980.
PubMed
24) Kizaki M, et al:Retinoid resistance in leukemic cells. Leuk Lymphoma 25(5-6):427-434, 1997.
 
25) Tallman M S, et al:Acute promyelocytic leukemia:evolving therapeutic strategies. Blood 99(3):759-767, 2002.
PubMed
26) Leoni F, et al:13-cis-retinoic acid treatment in patients with myelodysplastic syndrome. Acta Haematol 80(1):8-12, 1988.
PubMed
27) Motomura S, et al:The effect of 1-hydroxyvitamin D3 for prolongation of leukemic transformation-free survival in myelodysplastic syndromes. Am J Hematol 38(1):67-68, 1991.
PubMed
P.216 掲載の参考文献
1) Harris N L, et al:World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues:report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 17:3835-3849, 1999.
PubMed
2) Appelbaum F R, et al:Allogeneic marrow transplantation in the treatment of preleukemia. Ann Intern Med 100:689-693, 1984.
PubMed
3) Anderson J E:Bone marrow transplantation for myelodysplasia. Blood Rev 14:63-77, 2000.
PubMed
4) Sierra J, et al:Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia. Blood 100:1997-2004, 2002.
PubMed
5) Castro-Malaspina H, et al:Unrelated donor marrow transplantation for myelodysplastic syndromes:outcome analysis in 510 trans-plants facilitated by the National Marrow Donor Program. Blood 99:1943-1951, 2002.
 
6) Nevill T J, et al:Cytogenetic abnormalities in primary myelodysplastic syndrome are highly predictive of outcome after allogeneic bone marrow transplantation. Blood 92:1910-1917, 1998.
PubMed
7) Sutton L, et al:Factors influencing outcome in de novo myelodysplastic syndromes treated by allogeneic bone marrow transplanta-tion:a long-term study of 71 patients Societe Francaise de Greffe de Moelle. Blood 88:358-365, 1996.
 
8) Arnold R, et al:Unrelated bone marrow transplantation in patients with myelodys-plastic syndromes and secondary acute myeloid leukemia:an EBMT survey. Euro-pean Blood and Marrow Transplantation Group. Bone Marrow Transplant 21:1213-1216, 1998.
 
9) Runde V, et al:Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes:early transplantation is associated with improved outcome. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 21:255-261, 1998.
 
10) Appelbaum F R, et al:Allogeneic bone marrow transplantation for myelodysplastic syndrome:outcomes analysis according to IPSS score. Leukemia 12(Suppl 1):S25-29, 1998.
PubMed
11) Giralt S, et al:Nonablative stem cell transplantation for older patients with acute leukemias and myelodysplastic syndromes. Semin Hematol 39:57-62, 2002.
PubMed
12) Sandmaier B, et al:Nonmyeloablative conditioning for HLA-identical related allografts for hematologic malignancies. Blood 96(Suppl 1):479a, 2000.(abstr)
 
13) Kroger N, et al:A fludarabine-based dose reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome. Bone Marrow Transplant 28:643-647, 2001.
 
14) Parker J E, et al:Allogeneic stem cell transplantation(SCT) in MDS:Interim results of outcome following nonmyeloablative conditioning compared to standard preparative regimens. Blood 96(Suppl 1):554a, 2000.(abstr)
 
15) De Witte T, et al:Autologous bone marrow transplantation for patients with myelodysplastic syndrome(MDS) or acute myeloid leukemia following MDS. Chronic and Acute Leukemia Working Parties of the European Group for Blood and Marrow Transplantation. Blood 90:3853-3857, 1997.
 
16) de Witte T, et al:Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodys-plastic syndromes(MDSs) and acute myeloid leukemia following MDS. Blood 98:2326-2331, 2001.
 
P.228 掲載の参考文献
1) Greenberg P, et al:International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89(6):2079-2088, 1997.
PubMed
2) Alessandrino E P, et al:Evidence-and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the ltalian Society of Hematology. Haematologica 87(12):1286-1306, 2002.
 
3) Bowen D, et al:Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. Br J Haematol 120(2):187-200, 2003.
PubMed
4) Harris N L, et al:World Health Organization classification of neoplastic diseases of thehematopoietic and lymphoid tissues:report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997.
 
5) J Clin Oncol 17(12):3835-3849, 1999. Ohyashiki K, et al:Clinical and cytogenetic significance of myelodysplastic syndromeswith disease evolution. Cancer Genet Cytogenet 67(1):71-78, 1993.
 
6) Toyama K, et al:Clinical implications of chromosomal abnormalities in 401 patients with myelodysplastic syndromes:amulticentric study in Japan. Leukemia 7(4):499-508, 1993.
 
P.235 掲載の参考文献
1) Baldi G, et al:Cost/benefit relationship in 46 cases of myelodysplastic syndrome(RAEB and RAEB-T):aquality assurance analysis in clinical haematology. Haematologica 78:291-296, 1993.
 
2) Gupta P, et al:Long-term blood product transfusion support for patients with myelodysplastic syndromes(MDS):cost analysis and complications. Leuk Res 23:953-959, 1999.
PubMed
3) 正岡徹他:白血病治療の医療費. 癌と化療 18:1415-1420, 1991.
Medical*Online
4) 平岡 諦, 他:骨髄移植の医療費.今日の移植 4(Suppl 1):37-40, 1991.
 
5) 森山康子, 他:当院における急性骨髄性白血病の医療費について 寛解導入療法を中心に. 血腫瘍 38:90-94, 1999.
 
6) 鎌江伊三夫, 他:国内臨床試験に基づく造血幹細胞移植費用の検討. 今日の移植 16:37-43, 2003.
Medical*Online
7) 鎌江伊三夫, 他:造血幹細胞移植の費用効果分析. 今日の移植 16:145-154, 2003.
Medical*Online

第5章 骨髄異形成症候群のガイドライン

P.243 掲載の参考文献
1) National Comprehensive Cancer Network:Clinical Practice Guidelines in Oncology v.1. 2003.
 
2) Bennet P, et al:Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51:189-199, 1982.
 
3) World Health Organization classification of tumors. Pathology and genetics of tumors of haematopoietic and lymphoid tissues(Jaffe ES, et al, eds), p61-73. IARC Press Lyon, France, 2001.
 
4) Vardiman J W, et al:The World Health Organization(WHO classification of myeloid neoplasms. Blood 100:2292-2302, 2002.
PubMed
5) Greenberg P, et al:International scoring system for evaluating Prognosis in myelodysplastic syndromes. Blood 89:2079-2088, 1997.
PubMed
6) Greenberg PI:The role of hemopoietic growth factors in the treatment of myelodysplastic syndromes. Int J Pad Hem-Oncol 4:231-238, 1997.
 
7) Hellstrom-Lindberg E:Efficacy of erythropoietin in the myelodysplastic syndromes:Ameta-analysis of 205 patients from 17 studies. Br J Haematol 89:67-71, 1995.
 
8) Ohno R, et al:Treatment of myelodysplastic syndrome with orally administrated 1-b-d-arabinosylcytosine-5-stearylphosphate. Oncology 48:451-455, 1991.
 
9) Miller K B, et al:The evaluation of low dose cytarabin in the treatment of myelodysplastic syndrome. A phase-III intergroup study. Ann Hematol 65:162-168, 1992.
 
10) Silverman L R, et al:Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome:A study of the CALGB. J Clin Oncol 20:2429-2440, 2002.
 
11) Yoshida Y, et al:Arandomized study of alfacalcucol in the refractory myelodysplastic anemias. A Japanese cooperative study. Int J Clin Pharm Res 13:21-27, 1993.
 
12) Miyazawa K, et al:Vitamin K2 therapy for myelodysplastic syndromes(MDS) and post-MDS acute myeloid leukemia:information through a questionnaire survay of multi-center pilot studies in Japan. Leukemia 14:1156-1157, 2000.
 
13) Molldrem J, et al:Antithymocyte globulin for patients with myelodysplastic syndromes. Br J Haematol 99:699-705, 1997.
PubMed
14) Jonasova A, et al:Promising cyclosporin A therapy for myelodysplastic syndrome. Leuk Res 21:842, 1997.
 
15) Estey E H, et al:Comparison of idarubicin+ara-C, fludarabine+ara-C, and topotecan+ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excessblasts. Blood 98:3575-3583, 2001.
PubMed
16) Giralt E, et al:Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy:Harnessing graft-versus leukemia without myeloablative therapy. Blood 89:4531-4536, 2001.
 

書評

最近チェックした商品履歴

Loading...